From Autologous to Universal: Efficiency Strategies to Accelerate Next-Generation Immune Cell Therapy (CAR-NK/iPSC) R&D

Cell therapy is entering a phase where operational efficiency is becoming as decisive as scientific novelty. Autologous CAR-T has demonstrated clinical power, but the logistical bottlenecks of vein-to-vein orchestration create unavoidable friction. For programs aiming for late-stage scalability, this friction becomes a commercial non-starter. Meanwhile, “universal” or “off-the-shelf” approaches are increasingly attractive because they can convert a bespoke process into a repeatable product paradigm: standard inputs, standardised release tests, predictable scheduling, and a manufacturing cost curve that improves with experience rather than resetting for every patient. Drawing on platform-driven development experience and an economic structure built on patient-by-patient manufacturing, Creative Biolabs summarises actionable efficiency levers for CAR-NK and iPSC-derived immune cell programmes.